Automated Prediction of Neoadjuvant Chemoradiotherapy Response in Locally Advanced Cervical Cancer Using Hybrid Model-Based MRI Radiomics
- PMID: 38201314
- PMCID: PMC10795804
- DOI: 10.3390/diagnostics14010005
Automated Prediction of Neoadjuvant Chemoradiotherapy Response in Locally Advanced Cervical Cancer Using Hybrid Model-Based MRI Radiomics
Abstract
Background: This study aimed to develop a model that automatically predicts the neoadjuvant chemoradiotherapy (nCRT) response for patients with locally advanced cervical cancer (LACC) based on T2-weighted MR images and clinical parameters.
Methods: A total of 138 patients were enrolled, and T2-weighted MR images and clinical information of the patients before treatment were collected. Clinical information included age, stage, pathological type, squamous cell carcinoma (SCC) level, and lymph node status. A hybrid model extracted the domain-specific features from the computational radiomics system, the abstract features from the deep learning network, and the clinical parameters. Then, it employed an ensemble learning classifier weighted by logistic regression (LR) classifier, support vector machine (SVM) classifier, K-Nearest Neighbor (KNN) classifier, and Bayesian classifier to predict the pathologic complete response (pCR). The area under the receiver operating characteristics curve (AUC), accuracy (ACC), true positive rate (TPR), true negative rate (TNR), and precision were used as evaluation metrics.
Results: Among the 138 LACC patients, 74 were in the pCR group, and 64 were in the non-pCR group. There was no significant difference between the two cohorts in terms of tumor diameter (p = 0.787), lymph node (p = 0.068), and stage before radiotherapy (p = 0.846), respectively. The 109-dimension domain features and 1472-dimension abstract features from MRI images were used to form a hybrid model. The average AUC, ACC, TPR, TNR, and precision of the proposed hybrid model were about 0.80, 0.71, 0.75, 0.66, and 0.71, while the AUC values of using clinical parameters, domain-specific features, and abstract features alone were 0.61, 0.67 and 0.76, respectively. The AUC value of the model without an ensemble learning classifier was 0.76.
Conclusions: The proposed hybrid model can predict the radiotherapy response of patients with LACC, which might help radiation oncologists create personalized treatment plans for patients.
Keywords: MRI radiomics; automated prediction; cervical cancer; radiotherapy response.
Conflict of interest statement
The authors declare no conflict of interest.
Figures






Similar articles
-
External validation and comparison of MR-based radiomics models for predicting pathological complete response in locally advanced rectal cancer: a two-centre, multi-vendor study.Eur Radiol. 2023 Mar;33(3):1906-1917. doi: 10.1007/s00330-022-09204-5. Epub 2022 Nov 10. Eur Radiol. 2023. PMID: 36355199
-
Multimodal MRI-based deep-radiomics model predicts response in cervical cancer treated with neoadjuvant chemoradiotherapy.Sci Rep. 2024 Aug 17;14(1):19090. doi: 10.1038/s41598-024-70055-9. Sci Rep. 2024. PMID: 39154103 Free PMC article.
-
[A prediction model of pathological complete response in patients with locally advanced rectal cancer after PD-1 antibody combined with total neoadjuvant chemoradiotherapy based on MRI radiomics].Zhonghua Wei Chang Wai Ke Za Zhi. 2022 Mar 25;25(3):228-234. doi: 10.3760/cma.j.cn441530-20211222-00527. Zhonghua Wei Chang Wai Ke Za Zhi. 2022. PMID: 35340172 Clinical Trial. Chinese.
-
Endorectal ultrasound radiomics in locally advanced rectal cancer patients: despeckling and radiotherapy response prediction using machine learning.Abdom Radiol (NY). 2022 Nov;47(11):3645-3659. doi: 10.1007/s00261-022-03625-y. Epub 2022 Aug 11. Abdom Radiol (NY). 2022. PMID: 35951085
-
Radiomics-based prediction of two-year clinical outcome in locally advanced cervical cancer patients undergoing neoadjuvant chemoradiotherapy.Radiol Med. 2022 May;127(5):498-506. doi: 10.1007/s11547-022-01482-9. Epub 2022 Mar 24. Radiol Med. 2022. PMID: 35325372 Free PMC article. Review.
Cited by
-
PD-1 inhibitor plus concurrent chemoradiotherapy for high-risk locally advanced cervical cancer.Future Oncol. 2024;20(20):1415-1426. doi: 10.1080/14796694.2024.2342241. Epub 2024 Jun 3. Future Oncol. 2024. PMID: 38861299 Free PMC article.
-
Dysregulation of LINC01094 is involved in the pathogenesis of pulpitis by regulating the miR-340-5p expression.Odontology. 2025 Jul;113(3):1278-1287. doi: 10.1007/s10266-024-01046-5. Epub 2025 Jan 9. Odontology. 2025. PMID: 39786709
-
Predicting grade II-IV bone marrow suppression in patients with cervical cancer based on radiomics and dosiomics.Front Oncol. 2024 Nov 28;14:1493926. doi: 10.3389/fonc.2024.1493926. eCollection 2024. Front Oncol. 2024. PMID: 39669364 Free PMC article.
-
Artificial intelligence radiomics in the diagnosis, treatment, and prognosis of gynecological cancer: a literature review.Transl Cancer Res. 2025 Apr 30;14(4):2508-2532. doi: 10.21037/tcr-2025-618. Epub 2025 Apr 27. Transl Cancer Res. 2025. PMID: 40386259 Free PMC article. Review.
References
-
- Potter R., Tanderup K., Schmid M.P., Jurgenliemk-Schulz I., Haie-Meder C., Fokdal L.U., Sturdza A.E., Hoskin P., Mahantshetty U., Segedin B., et al. MRI-guided adaptive brachytherapy in locally advanced cervical cancer (EMBRACE-I): A multicentre prospective cohort study. Lancet Oncol. 2021;22:538–547. doi: 10.1016/S1470-2045(20)30753-1. - DOI - PubMed
-
- Chung H.C., Ros W., Delord J.P., Perets R., Italiano A., Shapira-Frommer R., Manzuk L., Piha-Paul S.A., Xu L., Zeigenfuss S., et al. Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Cervical Cancer: Results from the Phase II KEYNOTE-158 Study. J. Clin. Oncol. 2019;37:1470–1478. doi: 10.1200/JCO.18.01265. - DOI - PubMed
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials